Enanta Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also con...
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT03783897
- Locations
- πΊπΈ
Covance Clinical Research Unit, Madison, Wisconsin, United States
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT03755778
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03750383
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 8
- Registration Number
- NCT03748628
- Locations
- πΊπΈ
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 179
- Registration Number
- NCT03691623
- Locations
- π¬π§
hVIVO Services Limited (hVIVO), London, United Kingdom
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03610945
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Salt Lake City, Utah, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 134
- Registration Number
- NCT03421431
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈResearch Associates of South Florida, LLC, Miami, Florida, United States
π¨π¦Toronto Liver Centre, Toronto, Ontario, Canada
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
- Conditions
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT03394924
- Locations
- πΊπΈ
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
π§πͺUniversitair Ziekenhuis Gent, Gent, Oost-vlaanderen, Belgium
π³π±Vrije Universiteit Medisch Centrum, Amsterdam, Noord-holland, Netherlands
A Study of EDP-938 in Healthy Subjects
- First Posted Date
- 2017-12-27
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 90
- Registration Number
- NCT03384823
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT03213145
- Locations
- πΊπΈ
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States